Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).

García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Bayés-Genis A, Fernández-Nofrerías E, Vilalta Del Olmo V, Carrillo X, Ibáñez B, Worner F, Casanova J, Pueo E, González-Juanatey JR and 27 more

Show all authors

López-Pais J, Bardají A, Bonet G, Fuertes M, Rodríguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gómez-Talavera S, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MÁ, Miró-Casas E, Marsal JR, Sambola A, Lidón RM, Bañeras J, Elízaga J, Padilla F, Barrabés JA, Hausenloy DJ, Ferreira-González I, García-Dorado D

Basic research in cardiology25 Jan 2021Cited by 30 (Europe PMC)

PMID33495853DOI10.1007/s00395-021-00842-2PepBankPUB-33495853

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In STEMI patients receiving PPCI, infarct size did not differ between exenatide and placebo.
In plain wordsIn heart attack patients receiving PPCI, exenatide and placebo produced similar infarct sizes.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeInfarct size
Study
n = 222
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
Infarct size
25.1%
exenatide group
Infarct size
22.5%
placebo group
Source sentences
Summary
and the exenatide hypotheses (25.1 ± 11.5% in the exenatide group vs 22.5 ± 10.9% in the placebo group, P = 0.092).
3 context sentences(design, population, supporting numbers)
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
Report a problemFND-3349585301
02HumanRandomized controlled trialEfficacy outcome
In STEMI patients receiving PPCI, exenatide did not affect myocardial salvage index versus placebo.
In plain wordsIn heart attack patients receiving PPCI, exenatide did not improve myocardial salvage compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMyocardial salvage index
Study
n = 222
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
There were no effects with either RIC or exenatide on the secondary outcomes.
4 context sentences(design, population, supporting numbers)
Summary · context
The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume.
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
Report a problemFND-3349585302
03HumanRandomized controlled trialEfficacy outcome
In STEMI patients receiving PPCI, exenatide did not affect transmurality index versus placebo.
In plain wordsIn heart attack patients receiving PPCI, exenatide did not change transmurality index compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTransmurality index
Study
n = 222
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
There were no effects with either RIC or exenatide on the secondary outcomes.
4 context sentences(design, population, supporting numbers)
Summary · context
The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume.
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
Report a problemFND-3349585303
04HumanRandomized controlled trialEfficacy outcome
In STEMI patients receiving PPCI, exenatide did not affect left ventricular ejection fraction versus placebo.
In plain wordsIn heart attack patients receiving PPCI, exenatide did not improve heart pumping fraction compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeLeft ventricular ejection fraction
Study
n = 222
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
There were no effects with either RIC or exenatide on the secondary outcomes.
4 context sentences(design, population, supporting numbers)
Summary · context
The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume.
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
Report a problemFND-3349585304
05HumanRandomized controlled trialEfficacy outcome
In STEMI patients receiving PPCI, exenatide did not affect relative microvascular obstruction volume versus placebo.
In plain wordsIn heart attack patients receiving PPCI, exenatide did not reduce small vessel obstruction volume compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeRelative microvascular obstruction volume
Study
n = 222
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
There were no effects with either RIC or exenatide on the secondary outcomes.
4 context sentences(design, population, supporting numbers)
Summary · context
The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume.
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
Report a problemFND-3349585305
06HumanRandomized controlled trialSafety outcome
In STEMI patients, no unexpected adverse events or side effects of exenatide were observed.
In plain wordsIn heart attack patients, researchers observed no unexpected adverse events or side effects of exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableUnexpected adverse events or side effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Unexpected adverse events or side effects of RIC and exenatide were not observed.
3 context sentences(design, population, supporting numbers)
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
Report a problemFND-3349585307

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
In STEMI patients, RIC and exenatide showed no significant interaction on primary or secondary outcomes.
In plain wordsIn heart attack patients, the effects of RIC and exenatide showed no significant interaction.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTreatment interaction
Study
n = 222
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
There were no significant interactions between the two randomization factors on the primary or secondary outcomes.
3 context sentences(design, population, supporting numbers)
Summary · context
We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.
Summary · context
Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.
Summary · context
A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3349585306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).

Summary

Results from this study7

Studies that did not test the peptide alone1

Version history

Subjects

Publication types

MeSH terms

Keywords